×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:ARGX

argenx Stock Forecast, Price & News

$364.35
-0.20 (-0.05%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$354.10
$364.83
50-Day Range
$269.58
$364.55
52-Week Range
$249.50
$365.81
Volume
327,429 shs
Average Volume
277,955 shs
Market Capitalization
$19.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$362.94
30 days | 90 days | 365 days | Advanced Chart

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Stock Forecast (MarketRank)

Overall MarketRank

1.67 out of 5 stars

Medical Sector

926th out of 1,418 stocks

Biological Products, Except Diagnostic Industry

142nd out of 216 stocks

Analyst Opinion: 2.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
argenx logo

About argenx (NASDAQ:ARGX)

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

ARGX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
Fax
N/A
Employees
650
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$362.94
High Stock Price Forecast
$455.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
-0.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
18 Analysts

Profitability

Net Income
$-408.27 million
Net Margins
-147.47%
Pretax Margin
-74.11%

Debt

Sales & Book Value

Annual Sales
$539.42 million
Book Value
$49.05 per share

Miscellaneous

Free Float
N/A
Market Cap
$19.54 billion
Optionable
Optionable
Beta
1.11














argenx Frequently Asked Questions

Should I buy or sell argenx stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 1 hold rating, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx
or view top-rated stocks.

What is argenx's stock price forecast for 2022?

18 brokerages have issued 12 month price objectives for argenx's stock. Their ARGX stock forecasts range from $250.00 to $455.00. On average, they expect argenx's share price to reach $362.94 in the next year. This suggests that the stock has a possible downside of 0.4%.
View analysts' price targets for argenx
or view top-rated stocks among Wall Street analysts.

How has argenx's stock price performed in 2022?

argenx's stock was trading at $350.19 at the beginning of the year. Since then, ARGX stock has increased by 4.0% and is now trading at $364.35.
View the best growth stocks for 2022 here
.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for argenx
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) issued its earnings results on Thursday, May, 5th. The company reported ($4.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.08) by $0.72. argenx had a negative trailing twelve-month return on equity of 32.54% and a negative net margin of 147.47%. During the same quarter last year, the business posted ($0.81) EPS.
View argenx's earnings history
.

Who are argenx's key executives?

argenx's management team includes the following people:
  • Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc, CEO & Exec. Director (Age 50, Pay $1.28M)
  • Prof. Hans de Haard Ir, Ph.D., Co-Founder & Chief Scientific Officer (Age 62)
  • Mr. Karl Gubitz, Chief Financial Officer (Age 52)
  • Mr. R. Keith Woods, Chief Operating Officer (Age 54)
  • Mr. Arjen Lemmen M.Sc., VP of Corp. Devel. & Strategy (Age 37)
  • Dr. David L. Lacey M.D., Advisor (Age 70, Pay $19.71k)
  • Ms. Andria Wilk, Global Head of Quality (Age 48)
  • Mr. Filip Borgions, VP & Global Head of Technical Operations
  • Ms. Beth DelGiacco, VP and Global Head of Corp. Communications & Investor Relations
  • Ms. Malini Moorthy, Gen. Counsel (Age 52)

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (1.90%), Bellevue Group AG (1.78%), Capital World Investors (1.38%), BlackRock Inc. (1.26%), Artal Group S.A. (1.10%) and Federated Hermes Inc. (0.86%).

Which major investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., TimesSquare Capital Management LLC, Bellevue Group AG, Federated Hermes Inc., Invesco Ltd., Banque Pictet & Cie SA, and SG Americas Securities LLC.

Which major investors are buying argenx stock?

ARGX stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Goldman Sachs Group Inc., Artal Group S.A., Capital World Investors, Fiera Capital Corp, Woodline Partners LP, Fairmount Funds Management LLC, and Alyeska Investment Group L.P..

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $364.35.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $19.54 billion and generates $539.42 million in revenue each year. The company earns $-408.27 million in net income (profit) each year or ($11.540010) on an earnings per share basis.

How many employees does argenx have?

argenx employs 650 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for argenx is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at [email protected].

This page (NASDAQ:ARGX) was last updated on 6/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.